SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-027974
Filing Date
2023-06-14
Accepted
2023-06-14 16:30:56
Documents
14
Period of Report
2023-06-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20230608.htm   iXBRL 8-K 77912
2 EX-3.1 kalv-ex3_1.htm EX-3.1 190653
3 EX-10.1 kalv-ex10_1.htm EX-10.1 200136
  Complete submission text file 0000950170-23-027974.txt   651732

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230608_pre.xml EX-101.PRE 10230
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230608.xsd EX-101.SCH 2469
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230608_lab.xml EX-101.LAB 13905
8 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230608_htm.xml XML 4899
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 231014535
SIC: 2834 Pharmaceutical Preparations